xten peptide protein extends the in vivo half-life of therapeutics payloads - XTENlinker sequence Comprised of 36-residue pseudorepeats of only six amino acids XTEN Peptide Protein: Revolutionizing Therapeutic Lifespans

XTENpolymer The field of pharmaceutical development is continuously seeking innovative ways to enhance the efficacy and delivery of therapeutic agents. Central to this quest is the challenge of extending the in vivo half-life of peptides and proteins, thereby reducing the frequency of administration and improving patient outcomesMultivalent Antiviral XTEN–Peptide Conjugates with Long in .... XTEN peptide protein has emerged as a groundbreaking solution, offering a unique approach to prolonging the circulation time of biologically active molecules. This article delves into the science behind XTEN and its profound implications for drug delivery and therapeutic design.

At its core, XTEN refers to a class of unstructured, hydrophilic, and biodegradable protein polymers. These polymers are meticulously designed to increase the half-lives of therapeutic peptides and proteins.Extension of in vivo half-life of biologically active peptides via ... Unlike traditional methods, XTEN functions by genetically fusing with the therapeutic molecule, creating a larger conjugate with a significantly extended residence time in the body. This fusion leverages the principles of entity SEO, ensuring that the core concept of XTEN and its function is clearly understood and associated with its intended applicationsXTEN-Annexin A5: XTEN Allows Complete Expression of ....

The composition of XTEN is key to its efficacy. It is comprised of 36-residue pseudorepeats of only six amino acids (Alanine, Glutamic acid, Glycine, Proline, Serine, and Threonine). This specific amino acid sequence is deliberately chosen to ensure that XTEN lacks hydrophobic amino acid residues that often contribute to immunogenicity and complicate manufacture. This characteristic is crucial for its safe and nonimmunogenic profile, a critical consideration for any therapeutic agent intended for systemic administration. Research has demonstrated that XTEN has been shown to be safe and nonimmunogenic in several animal species, with XTEN-modified drugs progressing into clinical trials, underscoring its therapeutic potential.

The mechanism by which XTEN extends half-life is primarily through a "bulking" effect. By attaching to a protein or peptide, the XTEN polymer increases the overall size and hydrodynamic volume of the conjugate. This larger size hinders renal filtration, a primary route for the clearance of smaller molecules from the bloodstream. Consequently, the therapeutic agent remains in circulation for a much longer durationCharacterization of XTEN polymers (XTEN144 (1), .... This addresses the fundamental challenge of peptides and proteins often being rapidly cleared from the body, necessitating frequent dosing that can be inconvenient and costly for patients.

The versatility of XTEN is another significant advantage. It is described as an extended recombinant polypeptide (XTEN) compositions, capable of being linked to various therapeutic payloadsXTEN Data From Amunix, Inc. and Versartis, Inc. Featured .... This means that XTEN can be genetically fused to virtually any protein drug or peptide, offering a broad platform technology for half-life extension. This adaptability makes it a powerful tool for developing long-acting formulations of diverse therapeutics. For example, XTEN has been explored in conjunction with molecules like Glucagon-like peptide 2 (GLP2), an intestinal growth factor, and Glucagon-like peptide-1 (GLP-1) analogs, to enhance their therapeutic benefits in conditions such as inflammatory bowel disease and diabetes, respectively. Furthermore, XTEN has been investigated for its role in creating multivalent antiviral XTEN-peptide conjugates with long in vivo half life and enhanced solubility, highlighting its potential in infectious disease treatment.

Beyond its half-life extending capabilities, XTEN also offers manufacturing advantagesExtension of in vivo half-life of biologically active molecules .... The XTEN sequence has been specifically designed for good manufacturability, often being expressed in systems like Escherichia coli. This recombinant production method, combined with the inherent properties of the XTEN polymer, contributes to its low immunogenicity and good manufacturability, making it a more competitive alternative to established technologies like PEGylation.Identification of Active Coagulation Factor IX Variants with ... Indeed, XTEN is often seen as a biological alternative to PEGylation, offering similar benefits but with a protein-based, biodegradable approach.

In summary, the XTEN peptide protein represents a significant advancement in drug development. Its design as unstructured, nonrepetitive protein polymers allows for the effective extension of the in vivo half-life of therapeutic peptides and proteins. This is achieved through its capacity to be fused with active molecules, providing a bulking effect similar to other half-life extension technologies but with the added benefits of being biodegradable, nonimmunogenic, and manufacturable.XTEN™ is a class of unstructured hydrophilic, biodegradable protein polymersdesigned to increase the half-lives of therapeutic peptides and proteins. XTEN ... The ability to create XTEN conjugate compositions and its application in a wide range of therapeutic areas underscore its importance in the ongoing pursuit of more effective and patient-friendly treatments. The continued research and development around XTEN are paving the way for a future where many debilitating conditions can be managed with less frequent and more potent interventions.